|
Regen Biopharma Inc (RGBP) |
|
Regen Biopharma Inc
RGBP's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Regen Biopharma Inc growth rates, revenue grew
by 86.68 % in the third quarter of 2024 from the same quarter a year ago.
Ranking at No. 1563
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.18 %
Regen Biopharma Inc net loss increased from $0 millions, to $0 millions in third quarter of 2024,
• More on RGBP's Growth
|
|
Regen Biopharma Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Regen Biopharma Inc PEG ratio is at -0.15
Company is currently trading with Price to Cash flow multiple of 3.17 in trailing twelve-month period. |
Company |
15.86 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.26.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on RGBP's Valuation
|
|
|
|
|
Regen Biopharma Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Regen Biopharma Inc PEG ratio is at -0.15
Company is currently trading with Price to Cash flow multiple of 3.17 in trailing twelve-month period. |
Company |
15.86 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.26.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on RGBP's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com